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Abstract
Objective To compare 10 year revision rates for frequently used types
of primary total hip replacement to inform setting of a new benchmark
rate in England and Wales that will be of international relevance.
Design Retrospective cohort study.
Setting National Joint Registry.
Participants 239 000 patient records.
Main outcome measures Revision rates for five frequently used types
of total hip replacement that differed according to bearing surface and
fixation mode, encompassing 62% of all primary total hip replacements
in the National Joint Registry for England and Wales. Revision rates
were compared using Kaplan-Meier and competing risks analyses, and
five and 10 year rates were estimated using well fitting parametric
models.
Results Estimated revision rates at 10 years were 4% or below for four
of the five types of total hip replacement investigated. Rates differed
little according to Kaplan-Meier or competing risks analysis, but
differences between prosthesis types were more substantial. Cemented
prostheses with ceramic-on-polyethylene bearing surfaces had the lowest
revision rates (1.88-2.11% at 10 years depending on the method used),
and cementless prostheses with ceramic-on-ceramic bearing surfaces
had the highest revision rates (3.93-4.33%). Men were more likely to
receive revision of total hip replacement than were women, and this
difference was statistically significant for four of the five prosthesis types.
Conclusions Ten year revision rate estimates were all less than 5%,
and in some instances considerably less. The results suggest that the
current revision rate benchmark should be at least halved from 10% to
less than 5% at 10 years. This has implications for benchmarks
internationally.
Introduction
Total hip replacement is a successful intervention for hip
osteoarthritis. In the United States more than 300 000 total hip
replacements were undertaken in 2010,1 and in the United
Kingdom about 80 000 are undertaken annually.2 Many total
hip replacement components exist. Surgeons in the United
Kingdom can select from more than 150 different devices and
combinations of components.3 Ageing of host bone, wear in
bearing surfaces, and other contingencies mean that some total
hip replacements need replacing during a patient’s lifetime.
Surgical revision is a complex and demanding procedure that
is inconvenient, traumatic, and expensive. In the past, alarmingly
high revision rates were documented for some total hip
replacement designs. Catastrophic failure resulted in a 67% five
year revision rate for one device.4The 3MCapital hip, implanted
in more than 4000 patients in the United Kingdom from 1991,
raised concerns in 1995, and a Department of Health hazard
notice was issued in 1998.5 The DePuy ASR device was recalled
from the market in 2010 after more than 93 000 had been
implanted worldwide.6 7 Concerns have been raised about
devices with metal-on-metal bearing surfaces.8 9 In 2009 roughly
a third of hip replacements in the United States were
metal-on-metal.
Such episodes highlight the need for monitoring. Past use of
poor devices has been bad for patients and bad for the reputation
of orthopaedics and of clinicians, and it has contributed to waste
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of National Health Service resources. Effective measures are
needed to sieve out devices that fail to fulfil their promise and
to raise the performance of hip replacement. One way of
achieving this is the timely and stringent implementation of a
benchmark for revision rates. The benchmark can be
promulgated throughout the NHS and associated stakeholders,
allowing for quality assurance and organisational governance
procedures that encourage local compliance and improve quality.
Some people go further and suggest that any new product or
procedure should be compared with established standards of
care in a controlled trial,4 and others have commented that
“widespread surveillance of existing implants is urgently
needed.”10
The desire for monitoring has led to the creation of national
registries that achieve almost total coverage and can be used to
monitor performance.11 The National Joint Registry for England
and Wales holds information on more than 400 000 hip
replacements from 2003, including data on patients’ sex, age at
primary intervention, and time to revision.2 12 13 In 2000 the
National Institute for Health and Care Excellence (NICE)
suggested a 10 year benchmark of 10% for revision or a three
or five year revision rate commensurate with this 10 year
benchmark.14 In 2003 the NHS Supply Chain set up the
Orthopaedic Data Evaluation Panel (ODEP) to monitor
performance of prostheses against this benchmark.15 16
Manufacturers may non-compulsorily register a product, submit
evidence, and receive a rating of evidence quality. Total hip
replacement cups and stems are rated separately.
In 2011 ODEP identified 65 products that lacked an ODEP
rating.16 A recent systematic review found no evidence of
effectiveness for 24% of the total hip replacements recorded for
2011 in the National Joint Registry,17 and the authors suggested
that the ODEP system may allow scope for submission of
selective evidence.
Other international registries have published data on long term
revision rates,18 19 which provide a valuable standard for
assessment of the relevance and appropriateness of a benchmark.
They indicate that England has revision rates that are comparable
to internationally reported rates, although they are not the best.
The rates show that lowering the benchmark for England would
be reasonable. Conversely, publication of a benchmark will
support healthcare organisations in other countries in trying to
improve and assess their own performance. Other publications,
including National Joint Registry annual reports, have analysed
revision rates using Kaplan-Meier and competing risk
methods.2 20-23 In Kaplan-Meier analysis, the event of interest is
revision and other outcomes are censored; in competing risks
analysis, death before revision is a competing risk for revision
and only patients alive at the end of follow-up without revision
are censored. Kaplan-Meier analysis is believed to overestimate
the cumulative incidence of the event of interest compared with
competing risks analysis.20
We aimed to use different methods to compare 10 year revision
rates for frequently used types of primary total hip replacement
to inform the setting of a new NICE benchmark rate in England
and Wales that will be of international relevance.
Methods
Data came from the National Joint Registry for England and
Wales and contained records of primary surgery (resurfacing
and total hip replacement) between April 2003 andMarch 2012.
We included revision or death notified up to September 2012.
We used an iterative cross tabulation procedure applied to 386
556 useable records of total hip replacement undertaken for
osteoarthritis to identify four categories of prosthesis on the
basis of highest frequency of use of combinations of
components. We also included a fifth category that has recently
gained in popularity. Table 1⇓ lists the components of the five
total hip replacement categories studied (further details and data
on use are in web appendix A and B).
Analysis of revision rates
We used parametric models to estimate 10 year revision rates.
We used Stata 12 software for analyses. We judged goodness
of fit visually and according to Akaike’s information criterion.
For Kaplan-Meier analyses, we fitted bathtub, Weibull, and
loglogistic models with the stgenreg package of Crowther and
Lambert 2013 and flexible parametric models with the stmp2
package of Lambert and Royston 2009.24 25 We used bathtub
models to reflect perceived biological plausibility in describing
reducing risk after surgery and subsequent increasing risk,26-28
as both bone and prosthesis accumulate wear and tear.
Competing risks analysis used the stcompet package of Coviello
and Bogess 2004,29 and flexible parametric models were fitted
with the stmp2cif and stcompetadj packages of Hinchliffe and
Lambert 2012 and Coviello 2013.30 31 The subhazard procedure
of Fine and Gray 1999,32 as available in Stata, was followed by
least squares non-linear regression to fit Weibull and lognormal
models.
As patients’ age and sex influence performance of revision, we
stratified by sex and modelled 10 year revision rates for 70 year
old patients by using Kaplan-Meier and competing risks
methods.We also compared five year revision rates by category,
again using Kaplan-Meier and competing risks flexible
parametric models, adjusted for age and stratified by sex.
Results
The five categories comprised 239 089 patients, representing
62% of all eligible patients in the database and representative
of all eligible patients with respect to follow-up, age and sex
distributions, and American Society of Anesthesiologists’
physical condition grading (see appendices A and B). Figure
1⇓ illustrates the unadjusted cumulative incidence of revision
for each category of total hip replacement, according to
Kaplan-Meier and competing risks analyses. Competing risks
analysis delivered lower cumulative revision than Kaplan-Meier
analysis, but the difference is small for all categories; the
categories most altered by use of the competing risks method
had higher rates of death and were implanted in relatively older
patients. (For category A, the 95% confidence intervals of the
two flexible models did not overlap.)
Revision rates at 10 years were fitted using bathtub, Weibull,
loglogistic, and flexible parametric models for Kaplan-Meier
analyses and flexible parametric models for competing risks
analyses and were all considerably less than 4% except for the
cementless prostheses C (ceramic head (cementless stem) on
cementless hydroxyapatite coated metal cup (ceramic liner))
and B (metal head (cementless stem) on cementless
hydroxyapatite coated metal cup (polyethylene liner)) (table 2⇓
and fig 2⇓; further details in appendix C). The different revision
rate models delivered very similar 10 year estimates within each
total hip replacement category. Differences between categories
were greater than those between alternative methods of
modelling revision within a category. The 95% confidence
intervals for categories A and E did not overlap with those for
B and C. The results show that cemented and hybrid device
types seem to yield better revision performance than others.
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Median age across the combined categories was 70.4 years. The
populations receiving the five total hip replacement categories
differed by age and sex (fig 3⇓). Age distributions within
categories for men and for women were similar. Mean age
differed between categories by asmuch as 10 years (for example,
category C versus category A). Men had higher revision rates
than women according to both Kaplan-Meier (fig 4⇓) and
competing risks (appendix D) analyses. Except for category E,
this difference was statistically significant (P<0.05) both with
and without age stratification.
After stratifying by sex, we modelled 10 year revision for male
and female 70 year old patients by Kaplan-Meier and competing
risks methods. The ceramic head (cementless stem) on
cementless hydroxyapatite coated metal cup (ceramic liner)
category (C) remained the poorest performing category and
ceramic head (cemented stem) on cemented polyethylene cup
(category E) the best (table 3⇓; further details in appendix E).
Differences between sexes were of smaller magnitude than
differences between total hip replacement types. Categories C
and E have been used in younger populations, who typically
experience higher revision rates; adjustment for age should
favour their performance relative to the other three categories.
Table 4⇓ and figures 5⇓ and 6⇓ show the five year revision rates
for a patient with the average age for each category. Age
adjustment resulted in very small differences across an age span
from 50 to 70 years, varying between 0.03% (for women
receiving metal head (cementless stem) on cementless
hydroxyapatite coated metal cup (polyethylene liner) devices)
and 1.1% (for women receiving metal head (cemented stem) on
cemented polyethylene cup devices). Full results for revision
at five years for men and women aged 50, 60, and 70 years are
provided in appendix F. In most cases at five years, revision
rates were less than 2.5% for both men and women aged 50 to
70 years.
Discussion
We found that 10 year revision rates for five frequently used
categories of total hip replacement prosthesis were all less than
5% and that revision rates were higher for men than for women.
We concluded that the revision rate benchmark for England and
Wales at 10 years should be at least halved from 10% to 5%.
The National Joint Registry for England and Wales represents
a valuable resource providing statistical power and
comprehensiveness. However, some weaknesses are common
to such databases, even with careful observance of protocols
for data entry.33 34 These include a heavy reliance on revision
as an outcome rather than on pain or quality of life, omission
of variables that might confound analyses (such as activity levels
among recipients of different devices), and the possibility of
missing and duplicate entries. Nevertheless, in the absence of
evidence from randomised controlled trials, national registries
remain the best available evidence to assess performance of
devices.18 19 23 35
One of the strengths of this study is that our analyses have
explored all models previously used to investigate revision and
reflect the actual performance of devices as used in the United
Kingdom. Modelling of revision rates is valuable in this case,
as it uses information from all the observed data and does not
depend on idiosyncrasies in the data at any particular point in
time or on a period in which uncertainty is high owing to
progressive reduction in numbers at risk.
The extrapolated 10 year performance of different total hip
replacement devices reported here is compatible with previous
analyses of the National Joint Registry.2 23 Cemented devices
seem to have better revision performance than cementless
devices. Greater use of cementless as opposed to cemented
prostheses in 2008-09 (table 5⇓) reported for Australia and the
United Kingdom thus does not reflect the apparently superior
performance of cemented devices and differs from the
Scandinavian experience.18 19 However, a recent analysis of
Nordic registries found that from 2005 to 2011 use of cementless
devices increased dramatically. The authors attributed this to
“intensivemarketing ofmore expensive uncemented implants.”36
Variation in national practice coupled with lenient regulatory
requirements and a lack of randomised controlled trial evidence
may allow widespread use of suboptimal devices. Potentially
serious consequences are illustrated in experience of the 3M
Capital and the DePuy ASR devices.
A huge possible range of different combinations of prosthesis
components exists, and it was impractical to analyse all of them.
Selection of categories was based on frequency of use of
component parts. Four of the selected categories encompassed
the most frequently used types, and we selected the additional
smallest category because it has also gained in popularity more
recently (appendix B).
The five categories represented 62% of the total National Joint
Registry cohort and were representative of the total cohort with
respect to length of follow-up, sex and age distribution, and
American Society of Anesthesiologists grade distribution. Our
analyses indicate that for these five frequently used total hip
replacement categories, irrespective of analysis method, all 10
year revision rates were below 5% and some were considerably
less than 4%. At five years, only cementless devices exceeded
a 2% failure rate.
Our findings suggest that continuation of a benchmark of 10%
at 10 years might allow patients to have inferior total hip
replacement devices implanted. Some people argue that a
benchmark should not be so low as to stifle innovation, but too
a high benchmark would have little function. We consider that
a satisfactory benchmark could be set as a 4% revision rate at
10 years, although a 5% rate would allow for continuing
innovation while ensuring that poorly performing devices can
be phased out. We would also recommend that this benchmark
is reviewed within the next four years as new data become
available. The current Orthopaedic Data Evaluation Panel rating
system in the United Kingdom, although unique, is voluntary
and reactive. We agree with others that the current operation of
the system requires urgent modification.17
Conclusion
NICE has now published its revised benchmark and recommends
that the current benchmark at 10 years is reduced from 10% to
5%.37 Our data strongly support this change. As a result of this
work, we also consider that the regulation of device introduction
in the United Kingdom should be considered as a matter of
priority. Regulatory mechanisms, predicated on the assumption
that devices can be afforded a looser regulatory mechanism than
drugs, have allowed a very large number of brands of total hip
replacement to slip into routine use without rigorous monitoring
of effectiveness andwith a backlog of certification by the ODEP.
If the ODEPwere strengthened and randomised controlled trials
were demanded (as is standard for drugs by the regulatory
agencies), the use of devices that may be suboptimal for some
patients would be reduced. In the absence of a change in
regulatory procedures an effective updated benchmark is very
necessary, but it is a poor second best.
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What is already known on this topic
The total hip replacement revision benchmark of 10% at 10 years in England and Wales is under reconsideration
Revision rates vary between different types of total hip replacement device
Worryingly high revision rates have been documented for some devices and monitoring has been less effective than is desirable
What this study adds
Ten year revision rates were all less than 5% for five frequently used categories of total hip replacement prosthesis
Revision rates were higher for men than for women
The 10 year revision rate benchmark for England and Wales should be at least halved from 10% to 5%
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Tables
Table 1| Components of five frequently used categories of total hip replacement
NoAcronymCharacteristicsCategory
125 285CeMoPMetal head (cemented stem) on cemented polyethylene cupA
37 874CeLMoPMetal head (cementless stem) on cementless hydroxyapatite coated metal cup (polyethylene liner)B
34 754CeLCoCCeramic head (cementless stem) on cementless hydroxyapatite coated metal cup (ceramic liner)C
28 471HyMoPHybrid metal head (cemented stem) on cementless hydroxyapatite coated metal cup (polyethylene
liner)
D
12 705CeCoPCeramic head (cemented stem) on cemented polyethylene cupE
C=ceramic; Ce=cemented; CeL=cementless; Hy=hybrid; M=metal; P=polyethylene.
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Table 2| Estimated percentage revision rate (95% CI) at 10 years according to differing methods of analysis
Competing risk analysis: flexible model
Kaplan-Meier analysisCategory of total hip replacement
Flexible modelLoglogistic modelWeibull modelBathtub model
2.22 (2.06 to 2.38)2.58 (2.41 to 2.77)2.42 (2.28 to 2.55)2.42 (2.28 to 2.56)2.86 (2.65 to 3.07)A (CeMoP)
3.25 (2.85 to 3.66)3.71 (3.33 to 4.13)3.44 (3.15 to 3.73)3.45 (3.16 to 3.75)4.03 (3.53 to 4.54)B (CeLMoP)
3.96 (3.41 to 4.51)4.33 (3.83 to 4.90)3.93 (3.56 to 4.29)3.94 (3.57 to 4.32)4.73 (4.04 to 5.41)C (CeLCoC)
2.42 (2.03 to 2.81)2.77 (2.39 to 3.22)2.50 (2.21 to 2.79)2.51 (2.21 to 2.80)3.08 (2.59 to 3.57)D (HyMoP)
1.88 (1.37 to 2.40)1.96 (1.52 to 2.53)1.96 (1.54 to 2.38)1.97 (1.55 to 2.39)2.11 (1.49 to 2.72)E (CeCoP)
2.54 (2.41 to 2.67)2.92 (2.78 to 3.06)2.71 (2.61 to 2.81)2.72 (2.61 to 2.82)3.23 (3.06 to 3.40)A-E
C=ceramic; Ce=cemented; CeL=cementless; Hy=hybrid; M=metal; P=polyethylene.
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Table 3| Modelled 10 year revision rates (%) for 70 year old men and women
Flexible parametric modelLoglogistic modelWeibull modelBathtub modelCategory of
total hip
replacement FemaleMaleFemaleMaleFemaleMaleFemaleMale
2.67 (2.44 to
2.92)
2.93 (2.62 to
3.28)
2.53 (2.34 to
2.71)
2.79 (2.53 to
3.05)
2.53 (2.34 to
2.72)
2.78 (2.52 to
3.05)
2.97 (3.25 to
2.68)
3.18 (3.56 to
2.79)
A (CeMoP)
3.37 (2.92 to
3.88)
4.31 (3.66 to
5.07)
3.07 (2.72 to
3.43)
4.01 (3.50 to
4.53)
3.03 (2.67 to
3.38)
3.98 (3.46 to
4.50)
3.62 (4.23 to
3.01)
4.65 (5.53 to
3.77)
B (CeLMoP)
3.76 (3.07 to
4.61)
4.39 (3.58 to
5.37)
3.24 (2.70 to
3.78)
4.25 (3.53 to
4.96)
3.22 (2.67 to
3.76)
4.23 (3.51 to
4.95)
4.08 (5.01 to
3.15)
4.84 (5.98 to
3.69)
C (CeLCoC)
2.63 (2.17 to
3.18)
3.18 (2.54 to
3.98)
2.31 (1.95 to
2.67)
3.05 (2.50 to
3.61)
2.30 (1.94 to
2.65)
3.04 (2.48 to
3.60)
2.89 (3.48 to
2.30)
3.50 (4.40 to
2.60)
D (HyMoP)
1.68 (1.17 to
2.41)
2.10 (1.39 to
3.16)
1.67 (1.15 to
2.20)
2.11 (1.37 to
2.86)
1.68 (1.15 to
2.20)
2.12 (1.37 to
2.87)
1.80 (2.51 to
1.08)
2.26 (3.39 to
1.14)
E (CeCoP)
2.79 (2.62 to
2.97)
3.25 (3.02 to
3.50)
2.53 (2.41 to
2.66)
3.12 (2.93 to
3.31)
2.53 (2.40 to
2.65)
3.10 (2.92 to
3.29)
3.11 (3.32 to
2.90)
3.53 (3.83 to
3.24)
A-E
C=ceramic; Ce=cemented; CeL=cementless; Hy=hybrid; M=metal; P=polyethylene.
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Table 4| Five year revision rates—% (95% CI)—according to flexible parametric models
Competing risks flexible parametricKaplan-Meier flexible parametricSexCategory
1.52 (1.66 to 1.40)1.60 (1.48 to 1.74)MaleA (CeMoP)
1.20 (1.29 to 1.12)1.25 (1.17 to 1.34)Female
2.56 (2.28 to 2.87)2.64 (2.35 to 2.96)MaleB (CeLMoP)
2.06 (1.86 to 2.29)2.10 (1.90 to 2.33)Female
2.69 (2.39 to 3.03)2.72 (2.42 to 3.07)MaleC (CeLCoC)
2.32 (2.07 to 2.61)2.32 (2.06 to 2.60)Female
1.73 (1.46 to 2.05)1.79 (1.52 to 2.12)MaleD (HyMoP)
1.33 (1.15 to 1.54)1.38 (1.20 to 1.59)Female
1.11 (0.82 to 1.52)1.18 (0.89 to 1.58)MaleE (CeCoP)
0.91 (0.69 to 1.20)1.01 (0.79 to 1.30)Female
1.86 (1.97 to 1.76)1.94 (1.84 to 2.05)MaleA-E
1.45 (1.52 to 1.38)1.48 (1.42 to 1.55)Female
C=ceramic; Ce=cemented; CeL=cementless; Hy=hybrid; M=metal; P=polyethylene.
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Table 5| Relative use of different total hip replacement types as reported in different registry datasets
Resurface (%)Hybrid (%)Uncemented (%)Cemented (%)Registry
9324714Australia 2009
6153936England/Wales 2008
<1~24~22~50Norway 2008
14587Sweden 2008
Data from: www.hqip.org.uk/assets/Conferences-Summits/HQIP-ESQH-Euro-Summit-2012/Professor-Henrik-Malchau-Martyn-Porter-Pooling-data-across-Europe.
pdf.
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Figures
Fig 1 Kaplan-Meier and competing risk analyses of time to revision for different total hip replacement prostheses. C=ceramic;
Ce=cemented; CeL=cementless; Hy=hybrid; M=metal; P=polyethylene
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Fig 2 Estimated percent revision of different total hip replacement devices at 10 years according to Kaplan-Meier (KM) and
competing risks (CR) models. C=ceramic; Ce=cemented; CeL=cementless; Hy=hybrid; M=metal; P=polyethylene
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Fig 3 Age distribution for men and women by category. Vertical line represents 70 years of age. C=ceramic; Ce=cemented;
CeL=cementless; Hy=hybrid; M=metal; P=polyethylene
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Fig 4 Kaplan-Meier analysis of time to revision according to sex by total hip replacement category. C=ceramic; Ce=cemented;
CeL=cementless; Hy=hybrid; M=metal; P=polyethylene
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Fig 5 Flexible parametric models reflecting age distribution of each category in men. C=ceramic; Ce=cemented;
CeL=cementless; Hy=hybrid; M=metal; P=polyethylene
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Fig 6 Flexible parametric models reflecting age distribution of each category in women. C=ceramic; Ce=cemented;
CeL=cementless; Hy=hybrid; M=metal; P=polyethylene
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